UK markets closed

Natera, Inc. (NTRA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
101.65-0.50 (-0.49%)
As of 12:47PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close102.15
Open104.18
Bid99.06 x 1100
Ask99.48 x 800
Day's range92.97 - 104.18
52-week range16.87 - 127.19
Volume761,322
Avg. volume854,665
Market cap8.801B
Beta (5Y monthly)1.51
PE ratio (TTM)N/A
EPS (TTM)-2.84
Earnings date25 Feb 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est137.11
  • Natera and Personalis Partner for Personalized Monitoring in Oncology
    Business Wire

    Natera and Personalis Partner for Personalized Monitoring in Oncology

    Natera and Personalis Partner for Personalized Monitoring in Oncology

  • Is Natera (NASDAQ:NTRA) Using Too Much Debt?
    Simply Wall St.

    Is Natera (NASDAQ:NTRA) Using Too Much Debt?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

  • These Were the 5 Best Diagnostics Stocks of 2020
    Motley Fool

    These Were the 5 Best Diagnostics Stocks of 2020

    It's hard to think of an industry that was more impacted by the 2020 COVID pandemic than diagnostics. The often-overlooked part of the healthcare system sprang into action, testing more than 250 million people last year in the U.S. alone. Co-Diagnostics (NASDAQ: CODX), Aspira Women's Health (NASDAQ: AWH), Fulgent Genetics (NASDAQ: FLGT), GenMark Diagnostics (NASDAQ: GNMK), and Natera (NASDAQ: NTRA) were the five best-performing diagnostics companies last year among those with a market cap above $200 million.